Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.

about

A non-inferiority randomized controlled clinical trial comparing Unani formulation & psoralen plus ultraviolet A sol in chronic plaque psoriasis.

P2860

Q54984779-F1CE46A9-365F-4A97-9185-8CE7ED5728E7

P2860

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.

Item

http://www.wikidata.org/entity/Q41889404

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Effect of Oral PUVAsol on the ...... ving Chronic Plaque Psoriasis.

@en

type

Item

label

Effect of Oral PUVAsol on the ...... ving Chronic Plaque Psoriasis.

@en

prefLabel

Effect of Oral PUVAsol on the ...... ving Chronic Plaque Psoriasis.

@en

P1476

Effect of Oral PUVAsol on the ...... aving Chronic Plaque Psoriasis

@en

P2093

Madhur K Rastogi

http://www.w3.org/2001/XMLSchema#string

Nitin Mishra

http://www.w3.org/2001/XMLSchema#string

Puneet S Soodan

http://www.w3.org/2001/XMLSchema#string

P2860

The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.

Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment.

Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies.

Narrowband ultraviolet B versus psoralen plus ultraviolet A therapy for severe plaque psoriasis: an Indian perspective.

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.

Comparison of clinical and cost-effectiveness of psoralen + ultraviolet A versus psoralen + sunlight in the treatment of chronic plaque psoriasis in a developing economy.

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

Quality of life and site of the lesion in dermatological patients.

Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?

P304

291586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/291586

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Pratik Gahalaut

P577

2014-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266574375

http://www.w3.org/2001/XMLSchema#string

P698

25276121

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

P932

4167947

http://www.w3.org/2001/XMLSchema#string

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.

about

P2860

P2860

Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932